THERAPEUTIC APHERESIS, cilt.5, sa.1, ss.54-57, 2001 (SCI-Expanded)
Allogeneic peripheral blood Stem cell transplantation (PBSCT) is rarely applied for the treatment of severe aplastic anemia (SAA) because of questionable durablility of graftment and increased risk of P host disease (GVHD). We performed allogeneic PBSCT in 3 SAA patients from their human leukocyte antigen (HLA)-identical siblings. One received bone marrow after conditioning with cyclophoshamide (Cy) plus antithymocyte globulin. He had a second transplant with peripheral blood stem cells from the original donor because of a graft failure (GF). Two other patients received PBSCT as a first option. with Cy as the only conditioning drug. The 3 patients received short-term methotrexate and cyclosporine as a postgrafting, immunosupression. In the latter 2 cases, no GF has been observed, and a successful and complete hematological recovery was achieved and maintained for 28 and 25 months. respectively, In conclusion, PBSCT provides a quick and complete hematological recovery in SAA patients.